U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H30F2O6
Molecular Weight 452.4891
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUOCINOLONE ACETONIDE

SMILES

CC1(C)O[C@]2([H])C[C@@]3([H])[C@]4([H])C[C@@]([H])(C5=CC(=O)C=C[C@]5(C)[C@]4([C@]([H])(C[C@]3(C)[C@]2(C(=O)CO)O1)O)F)F

InChI

InChIKey=FEBLZLNTKCEFIT-VSXGLTOVSA-N
InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1

HIDE SMILES / InChI

Molecular Formula C24H30F2O6
Molecular Weight 452.4891
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012787s071lblrev.pdf

Fluocinolone Acetonide is a corticosteroid that binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. Cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In another words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Like other glucocorticoid agents Fluocinolone acetonide acts as a physiological antagonist to insulin by decreasing glycogenesis (formation of glycogen). It also promotes the breakdown of lipids (lipolysis), and proteins, leading to the mobilization of extrahepatic amino acids and ketone bodies. This leads to increased circulating glucose concentrations (in the blood). There is also decreased glycogen formation in the liver. Fluocinolone Acetonide is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (Retisert). Preparations containing Fluocinolone Acetonide were first marketed under the name Synalar.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SYNALAR

Approved Use

SYNALAR® Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteriod-responsive dermatoses.

Launch Date

-2.17123193E11
Primary
Retisert

Approved Use

Retisert is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Launch Date

1.11283195E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
54 ng/mL
0.8 mg single, topical
dose: 0.8 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
FLUOCINOLONE ACETONIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
354.8 ng × h/mL
0.8 mg single, topical
dose: 0.8 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
FLUOCINOLONE ACETONIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.8 h
0.8 mg single, topical
dose: 0.8 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
FLUOCINOLONE ACETONIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
6 ug 1 times / day multiple, intravitreal
Highest studied dose
Dose: 6 ug, 1 times / day
Route: intravitreal
Route: multiple
Dose: 6 ug, 1 times / day
Sources: Page: p.425
unhealthy, 24 –51
n = 6
Health Status: unhealthy
Condition: Subfoveal choroidal neovascularization
Age Group: 24 –51
Sex: M+F
Population Size: 6
Sources: Page: p.425
Disc. AE: Central retinal vein occlusion...
AEs leading to
discontinuation/dose reduction:
Central retinal vein occlusion (16.7%)
Sources: Page: p.425
2 ug 1 times / day multiple, intravitreal
Studied dose
Dose: 2 ug, 1 times / day
Route: intravitreal
Route: multiple
Dose: 2 ug, 1 times / day
Sources: Page: p.1196
unhealthy, 43.2
n = 5
Health Status: unhealthy
Condition: Posterior uveitis
Age Group: 43.2
Population Size: 5
Sources: Page: p.1196
0.6 ug 1 times / day multiple, intravitreal
Recommended
Dose: 0.6 ug, 1 times / day
Route: intravitreal
Route: multiple
Dose: 0.6 ug, 1 times / day
Sources: Page: p.1584
unhealthy
n = 127
Health Status: unhealthy
Condition: Diabetic macular edema
Population Size: 127
Sources: Page: p.1584
Disc. AE: Increased intraocular pressure...
AEs leading to
discontinuation/dose reduction:
Increased intraocular pressure (2.4%)
Sources: Page: p.1584
2 ug 1 times / day multiple, intravitreal
Studied dose
Dose: 2 ug, 1 times / day
Route: intravitreal
Route: multiple
Dose: 2 ug, 1 times / day
Sources: Page: p.17, 18
unhealthy
n = 168
Health Status: unhealthy
Condition: Non-infectious uveitis
Population Size: 168
Sources: Page: p.17, 18
Other AEs: Intraocular pressure abnormal...
AEs

AEs

AESignificanceDosePopulation
Central retinal vein occlusion 16.7%
Disc. AE
6 ug 1 times / day multiple, intravitreal
Highest studied dose
Dose: 6 ug, 1 times / day
Route: intravitreal
Route: multiple
Dose: 6 ug, 1 times / day
Sources: Page: p.425
unhealthy, 24 –51
n = 6
Health Status: unhealthy
Condition: Subfoveal choroidal neovascularization
Age Group: 24 –51
Sex: M+F
Population Size: 6
Sources: Page: p.425
Increased intraocular pressure 2.4%
Disc. AE
0.6 ug 1 times / day multiple, intravitreal
Recommended
Dose: 0.6 ug, 1 times / day
Route: intravitreal
Route: multiple
Dose: 0.6 ug, 1 times / day
Sources: Page: p.1584
unhealthy
n = 127
Health Status: unhealthy
Condition: Diabetic macular edema
Population Size: 127
Sources: Page: p.1584
Intraocular pressure abnormal
2 ug 1 times / day multiple, intravitreal
Studied dose
Dose: 2 ug, 1 times / day
Route: intravitreal
Route: multiple
Dose: 2 ug, 1 times / day
Sources: Page: p.17, 18
unhealthy
n = 168
Health Status: unhealthy
Condition: Non-infectious uveitis
Population Size: 168
Sources: Page: p.17, 18
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
yes
Drug as victim
PubMed

PubMed

TitleDatePubMed
Asthma steroid pharmacogenetics: a study strategy to identify replicated treatment responses.
2004
Fluocinolone acetonide topical oil for scalp psoriasis.
2004 Dec
Improved quality of life with effective treatment of facial melasma: the pigment trial.
2004 Jul-Aug
Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period.
2004 Jun
Flunisolide HFA for the treatment of asthma: an old friend reformulated.
2004 May
Treatment with inhaled flunisolide.
2004 May
In vitro effects of flunisolide on MMP-9, TIMP-1, fibronectin, TGF-beta1 release and apoptosis in sputum cells freshly isolated from mild to moderate asthmatics.
2004 Sep
Utilizing combination therapy to optimize melasma outcomes.
2004 Sep-Oct
Fluocinolone acetonide ophthalmic--Bausch & Lomb: fluocinolone acetonide Envision TD implant.
2005
Comparison of the analysis of corticosteroids using different techniques.
2005 Jan
Effects of drug treatment on inflammation and hyperreactivity of airways and on immune variables in cats with experimentally induced asthma.
2005 Jul
The nitrosterols--a step forward from the steroid anti-inflammatory drugs?
2005 Jul
Photochemistry and phototoxicity of fluocinolone 16,17-acetonide.
2005 Mar-Apr
Retisert (Bausch & Lomb/Control Delivery Systems).
2005 Nov
Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkane-flunisolide.
2005 Nov
A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads.
2005 Sep-Oct
Flunisolide decreases exhaled nitric oxide and nitrotyrosine levels in asthmatic children.
2006
A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream.
2006
Efficacy of nebulized flunisolide combined with salbutamol and ipratropium bromide in stable patients with moderate-to-severe chronic obstructive pulmonary disease.
2006
Once-daily intranasal corticosteroids for allergic rhinitis. Examining Treatment issues.
2006 Apr
Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial.
2006 Apr
Postinflammatory hyperpigmentation: evolving combination treatment strategies.
2006 Aug
Long-term release of fluocinolone acetonide using biodegradable fumarate-based polymers.
2006 Aug 28
[New drugs in the treatment of noninfectious uveitis].
2006 Dec
Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy.
2006 Dec
Ethnic considerations in the treatment of Hispanic and Latin-American patients with hyperpigmentation.
2006 Dec
Intravitreal steroids in the management of macular oedema.
2006 Dec
Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats.
2006 Jan-Feb
Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis.
2006 Jul
Dark brown scaly plaques on face and ears.
2006 Jun
Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.
2006 Jun
Community-based trial of a triple-combination agent for the treatment of facial melasma.
2006 Mar
Expression of TNF-alpha in oral lichen planus treated with fluocinolone acetonide 0.1%.
2006 Mar
Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion.
2006 Oct
Topical glucocorticosteroids in rhinitis: clinical aspects.
2006 Oct
Nebulized drug admixtures: effect on aerosol characteristics and albuterol output.
2006 Winter
Fluocinolone acetonide intravitreal sustained release device--a new addition to the armamentarium of uveitic management.
2007
Pharmacotherapies for diabetic retinopathy: present and future.
2007
Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
2007
Hypertrichosis as a side effect of inhaled steroids in children.
2007 Apr
Epithelial cells in the hair follicle bulge do not contribute to epidermal regeneration after glucocorticoid-induced cutaneous atrophy.
2007 Dec
Injectable, in situ forming poly(propylene fumarate)-based ocular drug delivery systems.
2007 Dec 1
Cost-effectiveness of a fixed combination of hydroquinone/tretinoin/fluocinolone cream compared with hydroquinone alone in the treatment of melasma.
2007 Feb
Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant.
2007 Feb
Strength and endurance of the respiratory and handgrip muscles after the use of flunisolide in normal subjects.
2007 Jul
Compressor/nebulizers differences in the nebulization of corticosteroids. The CODE study (Corticosteroids and Devices Efficiency).
2007 Jul-Aug
Vitreous band formation and the sustained-release, intravitreal fluocinolone (Retisert) implant.
2007 Jun
A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma.
2007 Mar
Retisert: is the new advance in treatment of uveitis a good one?
2007 Mar
Drug delivery methods for posterior segment disease.
2007 May
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: can also be used as intravitreal implant http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021737s000_PRNTLBL.pdf
generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion.
Route of Administration: Topical
Fluocinolone Acetonide (10(−6) M) inhibited the expression of inflammatory cytokines and matrix metalloproteinases in murine immortalized keratinocytes
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:53:42 UTC 2021
Edited
by admin
on Fri Jun 25 20:53:42 UTC 2021
Record UNII
0CD5FD6S2M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FLUOCINOLONE ACETONIDE
EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
FLUOCINOLONE ACETONIDE COMPONENT OF NEO-SYNALAR
Common Name English
TRI-LUMA COMPONENT FLUOCINOLONE ACETONIDE
Common Name English
ILUVIEN COMPONENT FLUOCINOLONE ACETONIDE
Brand Name English
FLUOCINOLONE ACETONIDE [INN]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 6,9-DIFLUORO-11,21-DIHYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))-, (6.ALPHA.,11.BETA.,16.ALPHA.)-
Common Name English
DERMOTIC
Brand Name English
FLUOCINOLIDE (ACETATE)
Common Name English
OTO-SYNALAR
Brand Name English
FLUOCINOLONE ACETONIDE [WHO-DD]
Common Name English
FLUOCINOLONE ACETONIDE [MART.]
Common Name English
ILUVIEN
Brand Name English
FLUOCINOLONE ACETONIDE [USAN]
Common Name English
FLUOCINOLONE ACETONIDE [USP]
Common Name English
SYNALAR
Brand Name English
FLUOCINOLONE ACETONIDE COMPONENT OF ILUVIEN
Brand Name English
DERMA-SMOOTHE/FS
Brand Name English
FLUOCET
Brand Name English
FLUOCINOLONE ACETONIDE [EP MONOGRAPH]
Common Name English
FLUOCINOLONE ACETONIDE [HSDB]
Common Name English
6.ALPHA.,9-DIFLUORO-11.BETA.,16.ALPHA.,17,21-TETRAHYDROXYPREGNA-1,4-DIENE-3,20-DIONE, CYCLIC 16,17-ACETAL WITH ACETONE
Common Name English
FLUOCINOLONE ACETONIDE [GREEN BOOK]
Common Name English
FLUOCINOLONE ACETONIDE [MI]
Common Name English
FLUOCINOLONE ACETONIDE [ORANGE BOOK]
Common Name English
FLUONID
Brand Name English
FLUOCINOLONE ACETONIDE [VANDF]
Common Name English
FLUOCINOLONE ACETONIDE [USP-RS]
Common Name English
FLUOCINOLONE ACETONIDE [JAN]
Common Name English
YUTIQ
Brand Name English
RETISERT
Brand Name English
OTOVEL COMPONENT OF FLUOCINOLONE ACETONIDE
Common Name English
FLUOCINOLONE ACETONIDE COMPONENT OF TRI-LUMA
Common Name English
OTOVEL COMPONENT FLUOCINOLONE ACETONIDE
Brand Name English
FLUOCINOLONE ACETONIDE COMPONENT OF OTOVEL
Common Name English
NSC-92339
Code English
FS SHAMPOO
Brand Name English
NEO-SYNALAR COMPONENT FLUOCINOLONE ACETONIDE
Common Name English
FLUCINOLONE ACETONIDE
Common Name English
FLUOCINOLONE ACETONIDE [USP MONOGRAPH]
Common Name English
CAPEX
Brand Name English
Classification Tree Code System Code
WHO-VATC QS02CA05
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
WHO-VATC QC05AA10
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
EU-Orphan Drug EU/3/16/1647
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
NCI_THESAURUS C521
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
WHO-VATC QD07CC02
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
WHO-VATC QS01BA15
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
WHO-ATC D07BC02
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
NDF-RT N0000175576
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
WHO-VATC QD07AC04
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
WHO-ATC S02BA08
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
WHO-ATC S02CA05
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
WHO-ATC D07AC04
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
WHO-ATC S01CA10
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
WHO-VATC QS01CA10
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
NDF-RT N0000175450
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
WHO-VATC QD07BC02
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
WHO-ATC D07CC02
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
WHO-ATC C05AA10
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
WHO-VATC QS02BA08
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
WHO-ATC S01BA15
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
Code System Code Type Description
MESH
D005446
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY
EVMPD
SUB07714MIG
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY
DRUG BANK
DB00591
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY
NCI_THESAURUS
C29055
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY
IUPHAR
7077
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY
EPA CompTox
67-73-2
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY
WIKIPEDIA
FLUOCINOLONE ACETONIDE
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY
CAS
67-73-2
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY
FDA UNII
0CD5FD6S2M
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY
PUBCHEM
6215
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY
RXCUI
4461
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
1204
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-668-5
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY
INN
1046
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY
HSDB
3083
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY
MERCK INDEX
M5451
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY Merck Index
USP_CATALOG
1275009
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY USP-RS
ChEMBL
CHEMBL989
Created by admin on Fri Jun 25 20:53:42 UTC 2021 , Edited by admin on Fri Jun 25 20:53:42 UTC 2021
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (UV)
EP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY